Literature DB >> 25049245

Experimental therapy with azoles against Candida guilliermondii.

Marta Sanchis1, Francisco Javier Pastor1, Javier Capilla1, Deanna A Sutton2, Annette W Fothergill2, Josep Guarro3.   

Abstract

We evaluated the in vitro killing activity of voriconazole (VRC) and posaconazole (PSC) against two clinical isolates of Candida guilliermondii. The two drugs showed fungistatic activity against both isolates and were effective in reducing kidney fungal burden in a neutropenic murine model of disseminated candidiasis in infected mice. PSC was significantly more effective than VRC against one of the strains. The serum levels of PSC and VRC were above the corresponding MICs for these isolates.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25049245      PMCID： PMC4187986          DOI： 10.1128/AAC.03051-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast.

Authors:  Vincenzo Savini; Chiara Catavitello; Daniela Onofrillo; Gioviana Masciarelli; Daniela Astolfi; Andrea Balbinot; Fabio Febbo; Claudio D'Amario; Domenico D'Antonio
Journal:  Mycoses       Date:  2010-10-29       Impact factor: 4.377

2.  Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.

Authors:  K L Oakley; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  In vivo pathogenicity of eight medically relevant Candida species in an animal model.

Authors:  M Arendrup; T Horn; N Frimodt-Møller
Journal:  Infection       Date:  2002-10       Impact factor: 3.553

4.  Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species.

Authors:  Rasmus H Jensen; Maiken C Arendrup
Journal:  J Clin Microbiol       Date:  2010-12-08       Impact factor: 5.948

5.  Comparison of posaconazole and voriconazole in vitro killing against Candida krusei.

Authors:  Emilia Cantón; Javier Pemán; Amparo Valentín; Maria Bosch; Ana Espinel-Ingroff; Miguel Gobernado
Journal:  Diagn Microbiol Infect Dis       Date:  2008-08-08       Impact factor: 2.803

6.  Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.

Authors:  Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

7.  Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans.

Authors:  M Mar Rodríguez; Enrique Calvo; Carolina Serena; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

8.  Efficacy of triazoles in a murine disseminated infection by Candida krusei.

Authors:  Marçal Mariné; F Javier Pastor; Carolina Serena; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

9.  Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.

Authors:  J Majithiya; A Sharp; A Parmar; D W Denning; P A Warn
Journal:  J Antimicrob Chemother       Date:  2008-11-13       Impact factor: 5.790

10.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Authors:  Peter A Warn; Andrew Sharp; Juan Mosquera; Jochen Spickermann; Anne Schmitt-Hoffmann; Markus Heep; David W Denning
Journal:  J Antimicrob Chemother       Date:  2006-10-27       Impact factor: 5.758
View more
  1 in total

1.  Antifungal Activity and Action Mechanism of Histatin 5-Halocidin Hybrid Peptides against Candida ssp.

Authors:  Juhye Han; Md Anirban Jyoti; Ho-Yeon Song; Woong Sik Jang
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.